Mohamed D.E. Abdelmaksoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed D.E. Abdelmaksoud has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Menha Swellam
Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt
2 shared publications Abd El-Haleem Ahmed
Department of Agricultural Biochemistry, Faculty of Agriculture and Natural Resources, Aswan University, Aswan, Egypt
1 shared publication- Abou El-Hamd H. Mohamed
Department of Chemistry, Faculty of Science, Aswan University, Aswan, Egypt
1 shared publication - Amal Ramadan
Biochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Giza, Egypt
1 shared publication Amira M. Nageeb
Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt
1 shared publicationHanan A. Soliman
Department of Biochemistry, Faculty of Science, Beni-suef University, Beni-Suef, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (4) , 71
Evaluation of the association of some circulating miRNA molecules in the metabolic syndrome
Purpose: The aim of this study was to investigate the possibility of including miRNA-371 and miRNA-143 in the early detection and diagnosis of the extent of the metabolic syndrome (MetS) in obese patients by measuring the expression of miRNA-143 and miRNA-371 in metabolically and pre-metabolically obese individuals and comparing the results with metabolically healthy obese controls. In addition, the study aimed to assess the correlation between the two types of miRNA and the criteria of MetS. Methods: The expression levels of miRNA-143 and miRNA-371 were determined using quantitative real-time polymerase chain reaction (PCR) for 135 obese patients who were divided into the following three different categories based on metabolic criteria: 1) metabolic syndrome obese (MetS) group, 2) pre-metabolic syndrome obese (PreMetS) group, and 3) metabolically healthy obese (MHO) group. Results: The results indicated a significant association of miRNA-143 and miRNA-371 with the MetS group compared with the PreMetS and MHO groups. As a result, the correlation analysis for these miRNAs revealed a large association with the results of the analysis for various factors, especially with regard to fasting glucose and lipid profiles in the MetS group. Conclusion: There was an association between obesity and MetS. This study was able to establish the role of miRNA-371 and miRNA-143 molecules in metabolically obese individuals. Therefore, by tracking the regulatory pathway of these molecules and expanding the understanding of the process of regulation and interference with the various metabolic pathways, this study could provide a deeper analysis and understanding of the MetS in obesity and the molecular causes leading to it.
- 1 January 2025
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (4) , 71
Open AccessEvaluation of the association of some circulating miRNA molecules in the metabolic syndrome
Purpose: The aim of this study was to investigate the possibility of including miRNA-371 and miRNA-143 in the early detection and diagnosis of the extent of the metabolic syndrome (MetS) in obese patients by measuring the expression of miRNA-143 and miRNA-371 in metabolically and pre-metabolically obese individuals and comparing the results with metabolically healthy obese controls. In addition, the study aimed to assess the correlation between the two types of miRNA and the criteria of MetS. Methods: The expression levels of miRNA-143 and miRNA-371 were determined using quantitative real-time polymerase chain reaction (PCR) for 135 obese patients who were divided into the following three different categories based on metabolic criteria: 1) metabolic syndrome obese (MetS) group, 2) pre-metabolic syndrome obese (PreMetS) group, and 3) metabolically healthy obese (MHO) group. Results: The results indicated a significant association of miRNA-143 and miRNA-371 with the MetS group compared with the PreMetS and MHO groups. As a result, the correlation analysis for these miRNAs revealed a large association with the results of the analysis for various factors, especially with regard to fasting glucose and lipid profiles in the MetS group. Conclusion: There was an association between obesity and MetS. This study was able to establish the role of miRNA-371 and miRNA-143 molecules in metabolically obese individuals. Therefore, by tracking the regulatory pathway of these molecules and expanding the understanding of the process of regulation and interference with the various metabolic pathways, this study could provide a deeper analysis and understanding of the MetS in obesity and the molecular causes leading to it.
- Open Access
- 1 January 2015
- Published by Wiley in IUBMB Life
- Vol. 67 (1) , 61-68
Aberrant methylation of APC and RARβ2 genes in breast cancer patients
Changes in the status of DNA methylation are one of the most common molecular alterations in human neoplasia. We aimed to identify epigenetic molecular markers in serum for early detection of breast cancer. Authors analyzed retrospectively the methylation status of RARβ2 and APC genes in serum samples from 121 breast cancer patients, 79 patients with benign breast diseases, and 66 healthy volunteers using methylation‐specific PCR. The methylated APC and RARβ2 were significantly higher in breast cancer patients (93.4%, 95.6%) than benign (7.8%, 14.5%) but not detected in healthy volunteers (0%) at (P < 0.0001). Both methylated genes showed no significant difference among clinicopathological factors apart from triple negative breast cancer patients as all of them (χ2 = 7.4, P = 0.007) reported to be methylated RARβ2 genes. Both methylated genes were detected in all grades and stages. Both sensitivities and specificities of the methylated genes for breast cancer detection were superior to traditional tumor markers in detection of breast cancer, early stage, low grade tumors, and triple negative breast cancer patients. Thus methylated APC and RARβ2 genes might be valuable serum‐based molecular markers for early detection of breast cancer. © 2015 IUBMB Life, 67(1):61–68, 2015
- 1 January 2015
- Published by Wiley in IUBMB Life
- Vol. 67 (1) , 61-68
Open AccessAberrant methylation of APC and RARβ2 genes in breast cancer patients
Changes in the status of DNA methylation are one of the most common molecular alterations in human neoplasia. We aimed to identify epigenetic molecular markers in serum for early detection of breast cancer. Authors analyzed retrospectively the methylation status of RARβ2 and APC genes in serum samples from 121 breast cancer patients, 79 patients with benign breast diseases, and 66 healthy volunteers using methylation‐specific PCR. The methylated APC and RARβ2 were significantly higher in breast cancer patients (93.4%, 95.6%) than benign (7.8%, 14.5%) but not detected in healthy volunteers (0%) at (P < 0.0001). Both methylated genes showed no significant difference among clinicopathological factors apart from triple negative breast cancer patients as all of them (χ2 = 7.4, P = 0.007) reported to be methylated RARβ2 genes. Both methylated genes were detected in all grades and stages. Both sensitivities and specificities of the methylated genes for breast cancer detection were superior to traditional tumor markers in detection of breast cancer, early stage, low grade tumors, and triple negative breast cancer patients. Thus methylated APC and RARβ2 genes might be valuable serum‐based molecular markers for early detection of breast cancer. © 2015 IUBMB Life, 67(1):61–68, 2015
- 10 October 2014
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 14 (6) , 409-417
Clinical implications of proteolytic activity imbalance in breast cancer diagnosis
BACKGROUND: Matrix metalloproteinase-9 and its tissue inhibitor TIMP-1 have been documented as putative tumor markers because of their involvement in cancer invasion and metastasis. OBJECTIVE: The aim of our study was to elucidate the diagnostic effi
- 10 October 2014
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 14 (6) , 409-417
Clinical implications of proteolytic activity imbalance in breast cancer diagnosis
BACKGROUND: Matrix metalloproteinase-9 and its tissue inhibitor TIMP-1 have been documented as putative tumor markers because of their involvement in cancer invasion and metastasis. OBJECTIVE: The aim of our study was to elucidate the diagnostic effi